Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders

Journal of Clinical Psychiatry

Volumn 69, Issue SUPPL. 4, 2008, Pages 15-20

  McDougle, Christopher J ^a   Stigler, Kimberly A ^a   Erickson, Craig A ^a   Posey, David J ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; HALOPERIDOL; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; BENZODIAZEPINE DERIVATIVE; DIBENZOTHIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE; THIAZOLE DERIVATIVE;

ADOLESCENT; AGGRESSION; AGITATION; AGRANULOCYTOSIS; ANGER; AUTISM; AUTOMUTILATION; CHILD; CHILD HEALTH; CLINICAL TRIAL; CONSTIPATION; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENURESIS; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; HEART PALPITATION; HUMAN; HYPERACTIVITY; HYPERSALIVATION; INCREASED APPETITE; IRRITABILITY; MENTAL DEFICIENCY; MONOTHERAPY; PRIORITY JOURNAL; PSYCHOSOCIAL WITHDRAWAL; QT PROLONGATION; RATING SCALE; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SOMNOLENCE; SPEECH DISORDER; STEREOTYPY; SYNCOPE; TACHYCARDIA; TARDIVE DYSKINESIA; THORAX PAIN; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; OBESITY; PRESCHOOL CHILD;

ADOLESCENT; AGGRESSION; ANTIPSYCHOTIC AGENTS; AUTISTIC DISORDER; BENZODIAZEPINES; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; CLOZAPINE; DIBENZOTHIAZEPINES; DISORDERS OF EXCESSIVE SOMNOLENCE; HUMANS; OBESITY; PIPERAZINES; QUINOLONES; RISPERIDONE; THIAZOLES;

EID: 46649086988     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
2. Posey DJ, McDougle CJ. The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders. Harv Rev Psychiatry 2000;8:45-63
3. McDougle CJ, Posey DJ, Stigler KA. Pharmacological treatments. In: Moldin SO, Rubenstein JLR, eds. Understanding Autism: From Basic Neuroscience to Treatment. Boca Raton, Fla: CRC Press; 2006:417-442
4. Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry 2008;69(suppl 4):26-36
5. Zuddas A, Ledda MG, Fratta A, et al. Clinical effects of clozapine on autistic disorder [letter]. Am J Psychiatry 1996;153:738
6. Chen NC, Bedair HS, McKay B, et al. Clozapine in the treatment of aggression in an adolescent with autistic disorder [letter]. J Clin Psychiatry 2001;62:479-480
7. Gobbi G, Pulvirenti L. Long-term treatment with clozapine in an adult with autistic disorder accompanied by aggressive behaviour [letter]. J Psychiatry Neurosci 2001;26:340-341
8. McCracken JT, McGough J, Shah B, et al, for Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002;347:314-321
9. Aman MG, Singh NN, Stewart AW, et al. The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 1985;5:485-491
10. McDougle CJ, Scahill L, Aman MG, et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the Research Units on Pediatric Psychopharmacology. Am J Psychiatry 2005;162:1142-1148
11. Freeman BJ, Ritvo ER, Yakota A, et al. A scale for rating symptoms of patients with the syndrome of autism in real life settings. J Am Acad Child Adolesc Psychiatry 1986;25:130-136
12. Scahill L, Riddle MA, McSwiggin-Hardin M, et al. Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity. J Am Acad Child Adolesc Psychiatry 1997;36:844-852
13. Research Units on Pediatric Psychopharmacology Autism Network. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am J Psychiatry 2005;162:1361-1369
14. Troost PW, Lahuis BE, Steenhuis MP, et al. Long term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. J Am Acad Child Adolesc Psychiatry 2005;44:1137-1144
15. Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004;114:e634-e641
16. Schopler E, Reichler RJ, DeVellis RF, et al. Toward objective classification of childhood autism: Childhood Autism Rating Scale (CARS). J Autism Dev Disord 1980;10:91-103
17. Nagaraj R, Singhi P, Malhi P. Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurol 2006;21:450-455
18. Luby J, Mrakotsky C, Stalets MM, et al. Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. J Child Adolesc Psychopharmacol 2006;16:575-587
19. Potenza MN, Holmes JP, Kanes SJ, et al. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol 1999;19:37-44
20. Malone RP, Cate J, Sheikh RM, et al. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry 2001;40:887-894
21. Kemner C, Willemsen-Swinkels SH, de Jonge M, et al. Open-label study of olanzapine in children with pervasive developmental disorder. J Clin Psychopharmacol 2002;22:455-460
22. Hollander E, Wasserman S, Swanson EN, et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol 2006;16:541-548
23. Martin A, Koenig K, Scahill L, et al. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 1999;9:99-107
24. Findling RL, McNamara NK, Gracious BL, et al. Quetiapine in nine youths with autistic disorder. J Child Adolesc Psychopharmacol 2004;14:287-294
25. Corson AH, Barkenbus JE, Posey DJ, et al. A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. J Clin Psychiatry 2004;65:1531-1536
26. Hardan AY, Jou RJ, Handen BL. Retrospective study of quetiapine in children and adolescents with pervasive developmental disorders. J Autism Dev Disord 2005;35: 387-391
27. McDougle CJ, Kem DL, Posey DJ. Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry 2002;41:921-927
28. Stigler KA, Posey DJ, McDougle CJ. Case report: aripiprazole for maladaptive behavior in pervasive developmental disorder. J Child Adolesc Psychopharmacol 2004;14:455-463
29. Valicenti-McDermott MR, Demb H. Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities. J Child Adolesc Psychopharmacol 2006;16:549-560
30. Stigler KA, Diener JT, Kohn AE, et al. Aripiprazole in Asperger's disorder and pervasive developmental disorders not otherwise specified: a 14-week prospective, open-label study [poster]. Presented at the 46th annual meeting of the American College of Neuropsychopharmacology; Dec 9-13, 2007; Boca Raton, Fla
31. McDougle CJ, Holmes JP, Carlson DC, et al. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry1998;55:633-641
32. Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 2007;90:147-164